Ignite Creation Date:
2024-05-06 @ 1:31 AM
Last Modification Date:
2024-10-26 @ 11:05 AM
Study NCT ID:
NCT01828112
Status:
COMPLETED
Last Update Posted:
2023-11-30
First Post:
2013-04-02
Brief Title:
LDK378 Versus Chemotherapy in ALK Rearranged ALK Positive Patients Previously Treated With Chemotherapy Platinum Doublet and Crizotinib
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CLDK378A2303
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None